Becton, Dickinson and Company (BDX)
- Previous Close
233.15 - Open
234.70 - Bid --
- Ask --
- Day's Range
233.50 - 235.05 - 52 Week Range
229.40 - 287.32 - Volume
322,028 - Avg. Volume
1,365,916 - Market Cap (intraday)
67.829B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
53.85 - EPS (TTM)
4.36 - Earnings Date May 2, 2024
- Forward Dividend & Yield 3.80 (1.63%)
- Ex-Dividend Date Mar 7, 2024
- 1y Target Est
278.54
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
www.bd.com73,000
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: BDX
Performance Overview: BDX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BDX
Valuation Measures
Market Cap
67.36B
Enterprise Value
82.29B
Trailing P/E
53.47
Forward P/E
17.21
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.47
Price/Book (mrq)
2.66
Enterprise Value/Revenue
4.22
Enterprise Value/EBITDA
19.21
Financial Highlights
Profitability and Income Statement
Profit Margin
6.44%
Return on Assets (ttm)
3.12%
Return on Equity (ttm)
5.12%
Revenue (ttm)
19.49B
Net Income Avi to Common (ttm)
1.26B
Diluted EPS (ttm)
4.36
Balance Sheet and Cash Flow
Total Cash (mrq)
1.18B
Total Debt/Equity (mrq)
63.60%
Levered Free Cash Flow (ttm)
3.79B
Research Analysis: BDX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: BDX
Analyst Report: Becton, Dickinson And Co.
Headquartered in Franklin Lakes, New Jersey, BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Its operations consist of three worldwide business segments: BD Medical, BD Life Sciences, and BD Interventional.
RatingBullishPrice TargetMarket Update: BDX, DINO
Stock markets were mixed on Monday morning ahead of the next read on inflation due out Wednesday morning via CPI. Expectations are for both headline and core CPI to rise a more-modest 0.3% from the 0.4% increase in February, for annual CPI to tick up to 3.5% from 3.2%, and core CPI to decrease to 3.7% from 3.8% last month. This week also marks the unofficial start of earnings season, with big banks J.P. Morgan Chase, Wells Fargo, and Citigroup reporting. The Dow and the S&P 500 were nearly flat, while and the Nasdaq gained 0.1%. Crude oil traded just above $86 per barrel and gold rose $4 to $2349 per ounce.
Large Cap US Pick List - April 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.